Stockscreener 앱 받기
2.05
1.91%
-0.04
시간 외 거래:
2.05
전일 마감가:
$2.09
열려 있는:
$2.05
하루 거래량:
31,425
Relative Volume:
0.71
시가총액:
$4.60M
수익:
-
순이익/손실:
$-20.85M
주가수익비율:
-0.127
EPS:
-16.1435
순현금흐름:
$-15.72M
1주 성능:
-29.79%
1개월 성능:
+17.14%
6개월 성능:
-23.51%
1년 성능:
+376.74%
1일 변동 폭
$2.03
$2.1951
1주일 범위
$2.00
$3.09
52주 변동 폭
$0.2701
$13.40
Indaptus Therapeutics Inc Stock (INDP) Company Profile
명칭
Indaptus Therapeutics Inc
전화
(646) 427-2727
주소
3 COLUMBUS CIRCLE, NEW YORK
Compare INDP vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INDP
Indaptus Therapeutics Inc
|
2.05 | 4.69M | 0 | -20.85M | -15.72M | -16.14 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Indaptus Therapeutics Inc 주식(INDP)의 최신 뉴스
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Large holders in Indaptus (INDP) revise stakes and end group status - Stock Titan
Indaptus Therapeutics (INDP) Stock: Is It a Good Entry Point | Indaptus Therapeutics misses EPS views, no revenue - Newser
Is It a Good Entry Point | Indaptus Therapeutics misses EPS views, no revenueVerified Stock Signals - Newser
Indaptus Therapeutics Appoints Tim Ruan and Johnny Fox Arrowsmith as Independent Directors; Amendment Reflects Legal Name Change - Minichart
Indaptus Therapeutics (INDP) refreshes board with two independents as one resigns - Stock Titan
Indaptus Therapeutics (INDP) reshapes board with two new independents and one exit - Stock Titan
Indaptus Therapeutics Adds Independent Directors Amid Board Refresh - TipRanks
Indaptus Therapeutics appoints two new independent directors and announces board changes By Investing.com - Investing.com South Africa
Indaptus Therapeutics appoints two new independent directors and announces board changes - Investing.com
Indaptus Therapeutics names Tim Ruan and Yi Zhang as independent directors; Matthew McMurdo resigns - TradingView
Indaptus (INDP) director Lu Qinglai submits initial Form 3 ownership - Stock Titan
Is Indaptus Therapeutics (INDP) stock trading at a premium valuation (Momentum Building) 2026-04-20Buy Signals - Newser
Indaptus Therapeutics (INDP) Stock: Why Automation Investment (Soars) 2026-04-18Trend Analysis - Xã Thanh Hà
Sino Lion Ventures Ltd Net Worth (2026) - GuruFocus
Junyi Dai Net Worth (2026) - GuruFocus
Yun Yao Net Worth (2026) - GuruFocus
Momentum Shift: Should I hold or sell Indaptus Therapeutics Inc nowInflation Watch & Daily Stock Trend Watchlist - baoquankhu1.vn
Published on: 2026-04-13 10:12:55 - baoquankhu1.vn
[SCHEDULE 13G/A] Indaptus Therapeutics, Inc. Amended Passive Investment Disclosure - Stock Titan
Risk Off: Why is Indaptus Therapeutics Inc stock going up2026 Volume Leaders & High Yield Equity Trading Tips - baoquankhu1.vn
Will Indaptus Therapeutics (INDP) Stock Outperform S&P 500 | Price at $1.54, Down 3.75%Stock Accumulation - Newser
Indaptus Therapeutics Appoints Yu Ding as New Chief Financial Officer Effective April 2026 - Minichart
Indaptus Therapeutics Names New CFO, Refreshes Board Oversight - The Globe and Mail
Indaptus Therapeutics announces CFO transition and new board appointment - Investing.com
INDP Technical Analysis & Stock Price Forecast - Intellectia AI
Indaptus Therapeutics announces CFO transition and new board appointment By Investing.com - Investing.com South Africa
Indaptus appoints Yu Ding as CFO; Nir Sassi resigns - TradingView — Track All Markets
Indaptus Therapeutics (INDP) names new CFO and independent director - Stock Titan
Indaptus Therapeutics Inc. (INDP) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Yun Yao converts preferred into 41.99M Indaptus (INDP) shares - Stock Titan
SINO LION VENTURES (INDP) discloses 38.9M-share Indaptus stake via preferred conversion - Stock Titan
Indaptus (INDP) CEO converts preferred stock into 11.25M common shares - Stock Titan
Volatility Watch: Is Indaptus Therapeutics Inc stock undervalued right now2026 Catalysts & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Risk Hedge: Whats next for Indaptus Therapeutics Inc stock2026 Action & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
Revenue Check: Why is Indaptus Therapeutics Inc stock going upTrade Risk Assessment & Stepwise Entry/Exit Trade Alerts - baoquankhu1.vn
Yun Yao Leads Investor Group, Secures CEO Change at Indaptus Therapeutics, Inc. with 37.8% Stake - TradingView
New investor group takes large control stake in Indaptus Therapeutics (INDP) - Stock Titan
Market Pulse: Why is Indaptus Therapeutics Inc stock going downWeekly Risk Summary & Safe Entry Zone Tips - baoquankhu1.vn
Rate Cut: Should I hold or sell Indaptus Therapeutics Inc nowTrade Analysis Report & AI Powered Market Entry Ideas - baoquankhu1.vn
Indaptus Therapeutics : 10-K 2025 Annual Report - marketscreener.com
Insider Buyers Lose US$40k As Indaptus Therapeutics Sheds US$583k - simplywall.st
Indaptus Therapeutics, Inc. Files Form 8-K Reporting Changes in Control – Key SEC Filing Details 3 - Minichart
Indaptus Therapeutics (INDP) shifts control and names Junyi Dai CEO-Chair - Stock Titan
Indaptus Therapeutics, Inc. Announces CEO Changes - MarketScreener
Lazar cuts Indaptus (NASDAQ: INDP) preferred stake, resigns as co‑CEO but stays on board - Stock Titan
Indaptus (INDP) director exits Series AAA stake, trims Series AA - Stock Titan
Short Covering: Does Indaptus Therapeutics Inc have declining or rising EPS2026 Major Catalysts & Safe Entry Zone Identification - baoquankhu1.vn
Market Outlook: Does Indaptus Therapeutics Inc have declining or rising EPSPortfolio Performance Report & Trade Opportunity Analysis Reports - baoquankhu1.vn
Indaptus Therapeutics, Inc. 2025 Annual Report: Company Overview, Risks, Investment Transaction, and Regulatory Compliance - Minichart
Indaptus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Indaptus Therapeutics Inc (INDP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.77%
0.25%
자본화:
|
볼륨(24시간):